AILERON THERAPEUTICS INC (ALRN)

Company Profile

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Waltham, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2017-06-29. The company is focused on developing medicines to make chemotherapy safer. Its ALRN-6924 product is a MDM2/MDMX dual inhibitor that leverages its peptide drug technology, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focused on treating patients with p53-mutated cancers. The company is developing ALRN-6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects without interrupting chemotherapy’s destruction of cancer cells. The company stabilizes peptides by stapling them with hydrocarbon bonds into their natural alpha-helical conformation. ALRN-6924 can pause cell division in cells with wild type, p53, include normal bone marrow cells and ALRN-6924 has no activity against cancer cells with mutations in p53.

Company Info

AILERON THERAPEUTICS INC

738 Main Street, Unit 398

Waltham MASSACHUSETTS 02472

P: 16179950900

CEO: Manuel C. Alves Aivado

Employees: 6

Website: https://aileronrx.com/